H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Aptose Biosciences to $7 from $23 and keeps a Buy rating on the shares. The analyst cites the company’s ongoing financial needs as it is approaches its tuspetinib pivotal trial for the target cut.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTO:
- Aptose Biosciences Secures $4.43 Million Funding
- Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Aptose Biosciences to sell 3.86M shares at $1.15 in registered direct offering
- Aptose Biosciences Concludes Agreement, Announces Update
- Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules